Cord blood banks have been established as an alternative source of hematopoietic reconstituting cells for allogeneic transplantation. More than 1,000 cord blood (CB) transplants have been performed from related or unrelated donors, with little or no resulting graftversus-host disease, even in cases with 1 or 2 HLA-antigen mismatches (1) . The major limitation to the widespread use of this stem cell source is the low number of cells obtained, which restricts its use in adults. Typically, CB recipients receive 10-fold fewer CD34 + cells and progenitors than do recipients of marrow or G-CSF-mobilized peripheral blood stem cells. In individuals 60 to 70 kg. the recovery of neutrophils and, particularly, platelets, is consequently delayed, and grafts fail in 16% of cases. These data provide a rationale for expanding CB progenitor cells ex vivo. Cord blood expansion studies began 7 years ago, using combinations of ILs (IL-3, IL-1, IL-6) and CSFs (G-CSF, GM-CSF) (2) . Subsequent studies used c-kit ligand (KL, variously termed steel factor or stem cell factor), Flk2Flt3 ligand (FL)m and thrombopoietin (Tpo) (3) (4) (5) (6) (7) (8) . These ligands seemed particularly effective in expanding cells with stem cell potential as detected in assays for longterm (5-8 weeks) culture-initiating cells (LTC-ICs) or "cobblestone" area-forming cells (CAFCs) (3, 6, 8) . Dramatic long-term expansion of CB progenitors and LTC-ICs has been reported by Piacibello et al (6, 7) , with a combination of FL, Tpo, KL, and IL-6 producing a 100-million-fold expansion of progenitors and a 270,000-fold expansion of LTCICs over 7 months.
The utility of existing assays for predicting human long-term engraftment potential of human stem cells is a matter of ongoing debate. Repopulation assays, in which human hematopoietic cells are injected intravenously into severe combined immunodeficient and nonobese diabetic (NOD/SCID) mice, have been used to follow up the expansion of hematopoietic populations that had been cultured ex vivo from cord blood (4, 7). Such assays have revealed a discrepancy between stem cell content as predicted by the in vitro surrogate assays (LTC-IC, CAFC), and in vivo repopulating ability (9) . In vitro assays can measure pluripotent cells with extensive self-renewal capacity, but they do not measure the additional properties of stem cells that contribute to their efficient homing to the bone marrow. Two such features have recently been revealed: the cell's ability to detect and respond to a chemokine gradient (8, 10) , and its upregulation of cytoadhesion molecules that allow it to be trapped by the endothelium of the marrow sinusoids (11) . Human CAFC, LTC-IC and NOD/SCID repopulating cells chemotax across membranes or endothelial barriers within 3 hours, in response to a marrow stroma-derived chemokine. Signaling by this stromal cell-derived factor-1 (SDF-1) through the CXCR4 receptor (8, 10) may be impaired after ex vivo expansion of CB, particularly with cytokine combinations that include IL-3 (8) . IL-6 enhanced CXCR4 expression on CD34 + cells (10) , and the 70-fold expansion of NOD/SCID repopulating cells reported after 9-10 weeks of culture of CB with IL-6 in combination with Tpo, FL, and KL, may in part be due to upregulation of CXCR4 (7). Conversely, the impaired NOD/SCID engraftment associated with the addition of IL-3 may be due in part to downregulation of the receptor.
A recent report in JCI revealed an important link between expression of CXCR4 and ability of CD34 + cells to undergo integrin-mediated arrest on vascular endothelium (11) . SDF-1, expressed on bone marrow endothelium, increased the adhesiveness of the integrins VLA-4 and LFA-1 to their respective endothelial ligands, VCAM-1 and ICAM-1, and this response was required to convert the loose, rolling 
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Commentary adhesion of CD34 + progenitors under shear flow into firm adhesion. Thus, impaired CXCR4 signaling or expression on cultured stem cells would be expected to reduce marrow engraftment by blunting the chemotactic response and the subsequent integrin-mediated arrest of stem cells in marrow sinusoids. The study of Ueda et al. in this issue of JCI is the latest contribution to the 7-year saga of optimizing CB expansion (12) . These authors report that a combination of SCF, FL, TPO, IL6, and a soluble form of the IL-6 receptor (sIL-6R) was superior to other formulations for expanding CB cells with NOD/SCID engraftment potential. The proportion of human CD45 cells engrafted in the mouse marrow at 10-12 weeks was 10-fold higher with 7-day-cultured CB cells than with fresh cells, and repopulating cells were expanded 4.2-fold by limiting dilution assay. These same investigators had earlier reported potent synergism between SCF and a complex of IL-6 and sIL-6R for cord blood progenitor expansion, and their current study extends the observed synergism to expansion of cells with in vivo stem cell potential. The rationale for the use of sIL-6R was based on the earlier observation (13) that human CD34 + LTC-ICs expressed the signaling component of the IL-6 receptor pathway but not the ligand-binding α-chain of the IL-6R (Figure 1 ).
Enhanced signaling through gp130 on stem cells may be advantageous in 2 ways: favoring self-renewal and upregulating CXCR4, which favors efficient homing to the marrow. A very high concentration of sIL-6R (1,000 ng/mL) was needed to obtain the expansion reported. Fischer et al. (14) have developed an IL-6 and sIL-6R fusion protein that was fully active at a 100-to 1,000-fold lower concentration than the combined unlinked IL-6 and IL-6R for stimulating hematopoietic progenitor expansion.
How soon can these improvements be translated into the clinic? Currently, clinical trials of ex vivo expanded cord blood are under way in the United States and Europe, using CD34 + selected cells expanded in Teflon culture bags, or nonselected CB mononuclear cells expanded in bioreactors. Various cytokine combinations are being tested, including FL, SCF, Tpo, and/or G-CSF or GM-CSF/IL-3 fusion protein. Upon availability of clinical grade IL-6/sIL-6R, it will be a relatively simple task to address whether its addition to the cytokine cocktails in current use for clinical expansion would lead to improved stem cell engraftment.
